AURORA 1 reports efficacy of voclosporin in lupus nephritis

被引：2
|
作者：
Moroni, Gabriella [1 ,2 ]
Ponticelli, Claudio [3 ]
机构：
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] IRCCS Humanitas Res Hosp, Milan, Italy
[3] IRCCS Osped Maggiore Policlin, Nephrol, Milan, Italy
来源：
NATURE REVIEWS NEPHROLOGY | 2021年 / 17卷 / 10期
关键词：
CYCLOSPORINE;
D O I：
10.1038/s41581-021-00460-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The AURORA 1 study reports that low-dose voclosporin added to standard immunosuppressive treatment improved rate of remission in patients with lupus nephritis. Further studies are needed to investigate the long-term efficacy and tolerability of voclosporin and to compare the effects of this treatment with those of low doses of tacrolimus or ciclosporin.
引用
收藏
页码：637 / 638
页数：2
相关论文
共 50 条
  • [21] Voclosporin improves outcomes in lupus nephritis
    不详
    NATURE REVIEWS RHEUMATOLOGY, 2021, 17 (07) : 378 - 378
  • [22] Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
    Arriens, Cristina
    Parikh, Samir
    Hodge, Lucy
    Mela, Chris
    Leher, Henry
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3288 - 3290
  • [23] Efficacy and Safety of Voclosporin Over 3 Years in Patients With Severe Lupus Nephritis
    Menn-Josephy, Hanni
    Truman, Matt
    Palmen, Mary
    Leher, Henry
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 33 - 33
  • [24] Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome Over 3 Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
    Parikh, Samir V.
    Arriens, Cristina
    Hodge, Lucy S.
    Mela, Christopher
    Leher, Henry
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 184 - 184
  • [25] Voclosporin in lupus nephritis: a profile of its use
    Esther S. Kim
    Susan J. Keam
    Drugs & Therapy Perspectives, 2022, 38 : 1 - 6
  • [26] Voclosporin in lupus nephritis: a profile of its use
    Kim, Esther S.
    Keam, Susan J.
    DRUGS & THERAPY PERSPECTIVES, 2022, 38 (01) : 1 - 6
  • [27] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Rovin, Brad H.
    Teng, Y. K. Onno
    Ginzler, Ellen M.
    Arriens, Cristina
    Caster, Dawn J.
    Romero-Diaz, Juanita
    Gibson, Keisha
    Kaplan, Joshua
    Lisk, Laura
    Navarra, Sandra
    Parikh, Samir V.
    Randhawa, Simrat
    Solomons, Neil
    Huizinga, Robert B.
    LANCET, 2021, 397 (10289): : 2070 - 2080
  • [28] AURORA PHASE 3 STUDY DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN)
    Arriens, C.
    Polyakova, S.
    Adzerikho, I.
    Randhawa, S.
    Solomons, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 172 - 173
  • [29] Long-Term Safety and Efficacy of Voclosporin in Patients With Lupus Nephritis and Low eGFR
    Saxena, Ramesh
    Collins, Christopher E.
    Birardi, Vanessa
    Pavlova-Wolf, Anna
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 184 - 185
  • [30] Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
    Arriens, Cristina
    Teng, Y. K. Onno
    Ginzler, Ellen M.
    Parikh, Samir V.
    Askanase, Anca D.
    Saxena, Amit
    Gibson, Keisha
    Caster, Dawn J.
    Atsumi, Tatsuya
    Lisk, Laura
    Randhawa, Simrat
    Gluck, Rashieda
    Solomons, Neil
    Huizinga, Robert B.
    ARTHRITIS CARE & RESEARCH, 2023, 75 (07) : 1399 - 1408
12345